|
|
|
| Webinar: Evolving Lentiviral Vector Manufacturing with Stable Production | As in vivo lentiviral programs expand, manufacturers need scalable, reliable production platforms that deliver consistent quality. Join Asimov's Sybil Danby and Adam Carcella to explore next-generation LV manufacturing strategies, including producer and packaging cell lines, and learn how synthetic biology and computational modeling are improving titer, reducing variability, and accelerating development for both ex vivo and in vivo therapies. Click here to learn more. |
|
|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene | Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone. | |
|
|
|
|
|
|
|
| Extrahepatic Delivery Of mRNA-LNP To Spleen | Poster | By Kalyan Golla, Sams Sadat, Hossein Yazdani Ahmadabadi, et al., Cytiva | In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies. |
|
|
| Extracellular Vesicle Isolation From Conditioned Media | Poster | By Elie Zakhem, Jae Jung, and Cameron Garland, et al., Repligen | Examine a scalable, sterile solution for isolating extracellular vesicles (EVs) in exosome therapeutics to enhance yield, purity, and commercial viability through innovative filtration technology. |
|
|
|
|
| Optimizing AAV8 Capsid Purification With Oversized GOI | Poster | By Yeonji Kim, Chris Brown, Jing Zhu, and Xiaojun Liu, Recipharm Advanced Bio | Strengthen AAV gene therapy quality and regulatory compliance. Modern AEX purification strategies achieve over 90% full capsid purity, even for oversized AAV8 vectors. |
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
